Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

(2012) Roger Bedimo et al.   AIDS

Body composition changes after switching from protease inhibitors to raltegravir

(2011) Adrian Curran et al.   AIDS

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

(2010) Hans‐Jürgen Stellbrink et al.   CLINICAL INFECTIOUS DISEASES

Continuous antiretroviral therapy decreases bone mineral density

(2009) Birgit Grund et al.   AIDS

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

(2009) Allison Martin et al.   CLINICAL INFECTIOUS DISEASES

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

(2009) Esteban Martínez et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

(2009) Paul E. Sax et al.   NEW ENGLAND JOURNAL OF MEDICINE

A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis

(2008) Jeannie Huang et al.   AIDS

Fracture Prevalence among Human Immunodeficiency Virus (HIV)-InfectedVersusNon-HIV-Infected Patients in a Large U.S. Healthcare System

(2008) Virginia A. Triant et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

(2008)   LANCET